



SRI VENKATESWARA COLLEGE OF PHARMACY

Approved by PCI & AICTE, New Delhi | Permanently Affiliated to JNTUA, Ananthapuramu
Accredited by NAAC, Bangaluru | Accredited by NBA, New Delhi for UG Programme under Tier-II
Recognized under section 2(f) & 12(B) of UGC Act, 1956
Recognized Research Centre for Pharmaceutical Sciences by JNTUA
Recognized in-House R & D by DSIR, New Delhi | DST-FIST Sponsored Institute
Ranked in the Rank Band 57th by NIRF 2019 Rankings by MHRD, Govt. of India



FARMACIA PRACTIA LETTRE JANUARY – JUNE 2018, VOL II ISSUE I NEWS LETTER FROM DEPARTMENT OF PHARMACY PRACTICE

Patron

Dr.Ravuri Venkataswamy

Chairman

SV Group of Institutions

Co-Patron

Mr. Ravuri Srinivas

Vice Chairman

SV Group of Institutions

Advisory Board

Dr.Shalini, MBBS, MD

Dr.L.C. Obulesu, MD

Dean, RVS Institute of Medical Sciences

Dr.M.R. Gayathri,

Director, Quest Life Sciences

Dr. Pandurangaiah,MS (ophth)

Medical Superintendent,

Government Hospital, Chittoor.

Editor-in-chief

Dr.K.Bhaskar Reddy, M.Pharm, Ph.D

Principal, Sri Venkateswara College of Pharmacy

Editor

Dr.C.Manisekhar, Pharm.D

Editorial Board

Dr.Lakshmi Sivasubramanian, M.Pharm, Ph.D

Dr.S.Hemalatha, M.Pharm, Ph.D

Dr.A.Saravana Kumar, M.Pharm, Ph.D

Dr.M.Rupesh Kumar, M.Pharm, Ph.D

Dr.K.Kavitha, M.Pharm, Ph.D

Dr.D.Jothieswari, M.Pharm, Ph.D

Dr.K.Raja Babu, Pharm.D

Dr.T.Ramakrishna, Pharm.D

Dr.Aleem Sarwar, Pharm.D

Student Editors

Dr.K.Bhargav, V year Pharm.D

V.K. Sharuk, VI year Pharm.D

A.Ammajan, III year Pharm.D

D.Durga Prasad II year Pharm.D

Principal's Message

It gives me immense pleasure that our department of pharmacy practice, Sri Venkateswara College of Pharmacy is releasing its news letter. The clinical pharmacy activity of our pharmacy practice department has gained strength in the last couple of years with the start of Pharm.D programme and our faculty and students are involved in patient services activities in clinical departments of RVS hospitals, a tertiary care super specialty hospital. It is indeed a matter of great pride and pleasure to share some of our experiences in patient care with everyone of you. Practice directions and other documents will be drafted and approved with the assistance of the standards of practice committee. The mandate of the college is to train high caliber health care professionals, offer specialized pharma services to the community, conduct research, offer consultancy services and participate in health policy formulation. The college has adequate and modern facilities to execute its mandate. The faculty and student editorial team deserve special appreciations and offer this news letter to our beloved chairman and vice chairman.

Dr. K. Bhaskar Reddy

Principal

Sri Venkateswara College of Pharmacy

IN THE CURRENT ISSUE

- **Drug profile**
- **Disease based information**
- **Departmental activities**

DRUG PROFILE

LUTATHERA

FDA approval date : 26 January 2018

Active ingredient : Lutetium Dotatate Lu-177

Strength : 10mCi/ML

Dosage form : Solution

Route of administration : Intravenous

Mechanism of action:

It binds to somatostatin receptor with highest affinity for sub type 2 receptor expressed cells and malignant somatostatin receptor positive tumors. The radio labelled compound is internalized and then formation of free radicals by the beta emission from the radioligand Lu 177 induces cellular damage in somatostatin receptor positive cells.

Adverse drug reaction :

The therapeutic effect of ¹⁷⁷Lu derives from the ionizing beta radiation it emits, however this can also be harmful to healthy tissue and organs.

BICTEGRAVIR

FDA approval date : 7February 2018

Active ingredient : 50 mg bicitgravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.[

Strength: Patients weighing ≥ 25 kg: 1 tablet taken 35nce daily with or without food.

Dosage form: Tablet

Route of administration: Intravenous

Mechanism of action: The two components of a dual-NRTI backbone have been shown in vitro to work synergistically to block reverse transcriptase. The third agent, an INSTI, inhibits the integration of viral DNA with human DNA. .

Adverse drug reaction : This drug should not be co-administered with dofetilide or rifampin.

DISEASE BASED INFORMATION

RHEUMATOID ARTHRITIS

Rheumatoid arthritis is an autoimmune disease that can cause joint pain and damage throughout body. The joint damage that RA causes usually happens on both sides of the body.

Signs and Symptoms:

Signs and symptoms of RA include:

- Pain, swelling, and stiffness in more than one joint
- Symmetrical joint involvement
- Joint deformity
- Unsteadiness when walking
- A general feeling of being unwell
- Fever
- Loss of function and mobility
- Weight loss
- Weakness

Risk factors

- Age 60 years or above
- Female
- Have specific genetic traits
- Have never given birth
- Have obesity
- Smoke tobacco or whose parents smoked when they were children

Complications

People with RA have a higher risk of some other conditions, including:

- Heart disease
- Obesity
- Diabetes
- High blood pressure

Diagnosis:

In its early stages, it may be difficult for a doctor to diagnose RA as it can resemble other conditions. However, early diagnosis and treatment are essential to slow the progression of the disease.

Blood tests:

A number of blood tests can help diagnose RA and rule out other conditions. They include:

- Anti-cyclic citrullinated peptide (anti-CCP)
- Rheumatoid factor
- Erythrocyte sedimentation rate (ESR or sed rate)
- C-reactive protein (CRP)
- X-ray
- MRI

Treatment :

Treatment will aim to:

- prevent flares and reduce their severity if they occur
- reduce inflammation to the joints
- relieve pain
- minimize any loss of function caused by pain, joint damage, or deformity
- slow down or prevent damage to the joints

Medications to manage symptoms

Disease-modifying antirheumatic drugs (DMARDs)

In 2015, the ACR Trusted Source recommended treatment with drugs known as disease modifying antirheumatic drugs (DMARDs), either alone or with other treatments. Methotrexate (Rheumatrex, Trexall) is an example of a DMARD. DMARDs affect how the immune system works. They can slow the progression of the RA and prevent permanent damage to the joints and other tissues by interfering with an overactive immune system.

Side effects can include:

- hair loss
- mouth ulcers
- nausea, stomach upset, and loose stool
- abnormal blood counts

Biologic treatments:

Biologic treatments, such as tumor necrosis factor-alpha (TNF-alpha) inhibitors, also change how the immune system works. When the human body faces an infection or other threat, it produces TNF-alpha, an inflammatory substance. TNF-alpha inhibitors suppress this substance and help prevent inflammation. TNF-alpha inhibitors can reduce pain, morning stiffness, and swollen or tender joints. People usually notice an improvement 2 weeks after starting treatment.

DEPARTMENTAL ACTIVITIES**Multi Specialty Mega Health Camp (IRCS), Date: 04.03.2018**

Pharm.D students were participated in multi specialty mega health camp and donated blood at ZP High School, GD Nellore Mandal, Chittoor.

MULTI SPECIALTY MEGA HEALTH CAMP (IRCS)

Breast Cancer awareness Programme on 26th March 2018

Pharm.D students were participated in Breast Cancer awareness Programme on 26th March 2018, at government hospital, chittoor.



Anti-microbial Resistance awareness Programme on 4th April 2018

Pharm.D students were participated in Anti-microbial Resistance awareness Programme on 4th April 2018 at government hospital, chittoor.



Suggestions and comments may kindly be sent to Editorial Board, Department of Pharmacy Practice, SVCOP, Chittoor.

Phone: 7729999181 Email: editorsvcopnewsletter@svcop.in